The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 382-388

  Donahue, Renee N ^a   McLaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Enkepalins; Low dose naltrexone; Opioid growth factor; Opioids; Ovarian cancer; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; NALTREXONE; OPIOID GROWTH FACTOR; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA; ENKEPHALIN, METHIONINE; FEMALE; HUMANS; MICE; MICE, NUDE; NALTREXONE; NARCOTIC ANTAGONISTS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECEPTORS, OPIOID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960457001     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.009     Document Type: Article

References (43)

1. P. Dinh, P. Harnett, M.J. Piccart-Gebhart, and A. Awada New therapies for ovarian cancer: cytotoxics and molecularly targeted agents Crit Rev Oncol Hematol 67 2008 103 112
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. N. Chobanian, and C.S. Dietrick Ovarian cancer Surg Clin North Am 88 2008 285 299 (Pubitemid 351434416)
4. E.J. Nam, and Y.T. Kim Alteration of cell-cycle regulation in epithelial ovarian cancer Int J Gynecol Cancer 18 2008 1169 1182
5. R.D. Donahue, P.J. McLaughlin, and I.S. Zagon Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis Am J Physiol Regul Integr Comp Physiol 296 2009 R1716 R1725
6. F. Cheng, I.S. Zagon, M.F. Verderame, and P.J. McLaughlin The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck Cancer Res 67 2007 10511 10518 (Pubitemid 350070827)
7. F. Cheng, P.J. McLaughlin, M.F. Verderame, and I.S. Zagon The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer Mol Cancer 7 2007 5 17
8. F. Cheng, P.J. McLaughlin, M.F. Verderame, and I.S. Zagon The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation Mol Biol Cell 1 2009 319 327
9. A.L. Misra Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone NIDA Res Monogr 28 1981 132 146 (Pubitemid 12235217)
10. P.J. McLaughlin, and I.S. Zagon Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems Life Sci 41 1987 1465 1472 (Pubitemid 17135576)
11. I.S. Zagon, and P.J. McLaughlin Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer Life Sci 35 1984 409 416 (Pubitemid 14083762)
12. J. Fogh, and G. Trempe New human tumor cell lines J. Fogh, Human tumor cells in vitro 1975 Plenum Publishing Corp New York 115 159
13. B.G. Ward, K. Wallace, J.H. Shepherd, and F.R. Balkwill Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice Cancer Res 47 1987 2662 2667 (Pubitemid 17083157)
14. T. Inaba, K. Ino, and H. Kajiyama Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma Gynecol Oncol 115 2009 185 192
15. 5]enkephalin) prevents the incidence and retards the growth of human colon cancer Am J Physiol 271 1996 R780 R786
16. P.J. McLaughlin, R.J. Levin, and I.S. Zagon Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice Cancer Lett 199 2003 209 217 (Pubitemid 37297714)
17. I.S. Zagon, S.D. Hytrek, J.P. Smith, and P.J. McLaughlin Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice Cancer Lett 112 1997 167 175 (Pubitemid 27104987)
18. S.D. Hytrek, P.J. McLaughlin, C.M. Lang, and I.S. Zagon Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone Cancer Lett 101 1996 159 164 (Pubitemid 26082268)
19. P.J. McLaughlin, S. Kreiner, C.R. Morgan, and I.S. Zagon Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor Int J Oncol 33 2008 751 757
20. I.S. Zagon, S. Kreiner, J.J. Heslop, A.B. Conway, C.R. Morgan, and P.J. McLaughlin Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor Int J Oncol 33 2008 317 323
21. I.S. Zagon, and P.J. McLaughlin Production and characterization of polyclonal and monoclonal antibodies to the zeta (zeta) opioid receptor Brain Res 630 1993 295 302 (Pubitemid 23342853)
22. A. Bandyopadhyay, F. López-Casillas, and S.N. Malik Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft Cancer Res 62 2002 4690 4695
23. R. Ravi, B. Mookerjee, and Z.M. Bhujwalla Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha Genes Dev 14 2000 34 44 (Pubitemid 30051577)
24. M.P. Shekhar, P. Nangia-Makker, S.R. Wolman, L. Tait, G.H. Heppner, and D.W. Visscher Direct action of estrogen on sequence of progression of human preneoplastic breast disease Am J Pathol 152 1998 1129 1132 (Pubitemid 28221863)
25. M.E. Valrance, A.H. Brunet, and J. Welsh Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo Endocrinology 148 2007 4887 4894 (Pubitemid 47481504)
26. G. Massazza, A. Tomasoni, and V. Lucchini Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy Int J Cancer 44 1989 494 500 (Pubitemid 19229310)
27. J.R. Jaglowski, I.S. Zagon, B.R. Stack, M.F. Verderame, A.E. Leure-duPree, and J.D. Manning Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck Cancer Chemother Pharmacol 56 2005 97 104 (Pubitemid 41201762)
28. I.S. Zagon, J.R. Jaglowski, M.F. Verderame, J.P. Smith, A.E. Leure-duPree, and P.J. McLaughlin Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma Cancer Chemother Pharmacol 56 2005 510 520 (Pubitemid 41549153)
29. I.S. Zagon, R.N. Donahue, and P.J. McLaughlin Opioid growth factor-opioid growth factor receptor axis is a physiological determinant on cell proliferation in diverse human cancers Am J Physiol Regul Integr Comp Physiol 297 2009 R1154 R1161
30. I.S. Zagon, and P.J. McLaughlin Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure Mol Brain Res 33 1995 111 120
31. I.S. Zagon, D.M. Gibo, and P.J. McLaughlin Ontogeny of the zeta (ζ), the opioid growth factor receptor, in the rat brain Brain Res 596 1992 149 156
32. I. Tegeder, and G. Geisslinger Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications Pharmacol Rev 56 2004 351 369 (Pubitemid 39096595)
33. I.S. Zagon, and P.J. McLaughlin Opioids and the apoptotic pathway in human cancer cells Neuropeptides 37 2003 79 88 (Pubitemid 37421490)
34. P.J. McLaughlin, R.J. Levin, and I.S. Zagon Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice Cancer Lett 199 2003 209 217 (Pubitemid 37297714)
35. I.S. Zagon, S.D. Hytrek, J.P. Smith, and P.J. McLaughlin Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice Cancer Lett 112 1997 167 175 (Pubitemid 27104987)
36. I.S. Zagon, and P.J. McLaughlin Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors Brain Res 480 1989 16 28 (Pubitemid 19050192)
37. J. Blebea, J.E. Mazo, and T.K. Kihara Opioid growth factor modulates angiogenesis J Vasc Surg 32 2000 364 373 (Pubitemid 30644951)
38. J. Blebea, J.H. Vu, S. Assadnia, P.J. McLaughlin, R.G. Atnip, and I.S. Zagon Differential effects of vascular growth factors on arterial and venous angiogenesis J Vasc Surg 35 2002 532 538 (Pubitemid 44718600)
39. D. Marchetti, C. Pisaon, G. Facchini, G. Salvatore, F.P. Magazzino, and S. Losito First-line treatment of advanced ovarian cancer: current research and perspectives Expert Rev Anticancer Ther 10 2010 47 60
40. J.P. Smith, R.L. Conter, and S.I. Bingaman Treatment of advanced pancreatic cancer with opioid growth factor: phase I Anticancer drugs 15 2004 203 209 (Pubitemid 38429411)
41. J.P. Smith, S.I. Bingaman, D.T. Mauger, H.A. Harvey, L.M. Demers, and I.S. Zagon Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer Open Access J Clinical Trials 2 2010 1 12
42. J.P. Smith, H. Stock, S. Bingaman, D. Mauger, M. Rogosnitzky, and I.S. Zagon Low-dose naltrexone therapy improves active Crohn's disease Am J Gastroenterol 102 2007 820 828 (Pubitemid 46496605)
43. J.P. Gonzalez, and R.N. Brogden Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence Drugs 35 1988 192 213